Abstract:Background Liver targeting drug delivery systems can improve the curative effects and relieve the cytotoxicity of the chemotherapy drugs in the treatment of liver diseases. Nanoparticles carrying therapeutic drugs are currently under hot investigation with great clinical significance. This study was aimed to investigate the different tissue distribution of the adriamycin polybutylcyanoacrylate nanoparticle (ADM-PBCA-NP) in the mice body after an injection via lateral tail vein, and to study the liver targeting effects of ADM-PBCA-NP in different diameters on normal mice liver.Methods One hundred and eighty Kunming mice were randomly divided into 6 groups with 30 mice in each group (5 treatment groups of ADM-PBCA-NP in the different diameter ranges, non-conjugated free adriamycin injection was employed as the control group). A single dose of either conjugated or free adriamycin equaled 2 mg/kg of body weight was delivered via the tail vein. Five mice in each trail were sacrificed at 5, 15, 30 minutes, 1, 5 and 12 hours postinjection, respectively. The adriamycin concentrations in the respectively collected liver, kidney, spleen, heart, lung and plasma were demonstrated using a high performance liquid chromatography with fluorescence detector.Results Compared with the control group, adriamycin was hardly detected in the heart muscle of the treatment groups (P < 0.05). The nanoparticle-conjugated adriamycin was cleaned up quickly from the kidney tissue. The adriamycin concentrations of the mice liver and spleen in the experimental groups were significantly higher than that in the control group, except for the group with the nanoparticles diameters of (22.3 +/- 6.2) nm (P < 0.05). The ADM-PBCA-NP in (101.0 +/- 20.3) nm diameter had the highest liver distribution, and the second highest adriamycin distribution in liver was the group of (143.0 +/- 23.5) nm diameter (P < 0.05). Moreover, adriamycin was released slowly in the liver during the detection period in the experimental groups. ADM-PBCA-NP in (22.3 +/- 6.2) nm diameter was not distributed in the tissue of the liver, kidney, heart, spleen, and lung.Conclusions ADM-PBCA-NP in 100-150 nm diameter range has the best liver targeting with a characteristic of slow medicine release. It also decreases the medicine distribution in the heart, kidney and lung. In the treatment of liver cancer, the polybutylcyanoacrylate, nanoparticles system has a good liver targeting ability, which increases the anticancer activity and markedly decreases the toxicity of adriamycin.

STUDY ON LIVER TARGETED VALACICLOVIR POLYBUTYLCYANOACRYLATE NANOPARTICLES

Study on Liver Targeting and Hepatocytes Permeable Valaciclovir Polybutylcyanoacrylate Nanoparticles.

[Preparation of Valaciclovir Loaded Bovine Serum Albumin Nanoparticles Surface-Modified with Glycyrrhizin and Its Characteristics of Targeting to Liver].

[Study on Liver Targeting and Sustained Release Hydroxycamptothecin Polybutylcyanoacrylate Nanoparticles].

Liver Targeting and the Delayed Drug Release of the Nanoparticles of Adriamycin Polybutylcyanoacrylate in Mice

Synthesis of Bile-acid-carrying Polymer and Its Application in Surface Modification of Nanoparticles for Hepatic Cell Targeting

Liver-Targeted Co-delivery of Entecavir and Glycyrrhetinic Acid Based on Albumin Nanoparticle To Enhance the Accumulation of Entecavir

Preparation, characterization and controlled release of liver-targeting nanoparticles from the amphiphilic random copolymer

Study on Preparation of Acyclovir Liposomes and Its Role in Inhibiting Hepatitics B in Vitro

N,N,N-trimethylchitosan-poly (n-butylcyanoacrylate) core-shell nanoparticles as a potential oral delivery system for acyclovir

Preliminary Study of Liver-targeting of Hepatitis B Immunoglobulin Polybutylcynaoacrylate Nanoparticles

Synthesis of cholic-acid-carrying polymer and in-vitro evaluation of hepatoma-targeting nanoparticles decorated with the polymer.

Novel Designed Polymer–acyclovir Conjugates with Linker‐controlled Drug Release and Hepatoma Cell Targeting

Study on the Liver Targeting of Oleanolic Acid Loaded Polybutylcyanoacrylate Nanocapsules in Mice

Anti-HBV effect of targeted lamivudy palmitate solid lipid nano-particles

Liver Targeting and Anti-Hbv Activity of Reconstituted HDL–acyclovir Palmitate Complex

[Preparation of Albendazole Polybutycyanocrylate Nanoparticles and Study on Its Pharmaceutical Properties and Tissue Distribution].

Chemoenzymatic Synthesis, Characterization, and Controlled Release of Functional Polymeric Prodrugs with Acyclovir As Pendant

Alternative Albendazole Polybutylcyanoacrylate Nanoparticles Preparation, Pharmaceutical Properties and Tissue Distribution in Rats

High yield synthesis,structure confirm of acyclovir palmitate and its role in inhibiting hepatitics B in vitro

Cytotoxicity and acute toxicity study on vinblastine (VLB) nanoparticles.